A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis

Therapuetic Areas:Pulmonary / Respiratory Diseases
Age Range:18 - Any
Start Date:March 2016

Use our guide to learn which trials are right for you!

A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

This study is being conducted to evaluate the safety, tolerability, and activity of 400 mg
of KD025 once-daily (QD) compared to standard of care (SOC) in male and
postmenopausal/surgically sterilized female subjects with IPF.

Thirty-six (36) male or postmenopausal/surgically sterilized female subjects with IPF who
are eligible, will be randomly enrolled in a 2:1 ratio (KD025 to SOC) to one of two
treatment groups. Subjects randomized to Treatment Group 1 will receive KD025 400 mg QD
orally for 24 weeks. Subjects randomized to Treatment Group 2 will receive SOC (as deemed
appropriate by the investigator). Subjects randomized to SOC will be treated exactly the
same as subjects on KD025 and undergo all tests in similar fashion.

Inclusion Criteria:

- Adult male and postmenopausal/surgically sterilized female subjects at least 18 years
of age (if female, is surgically sterilized [ie, total hysterectomy, or bilateral

- Able to provide written informed consent before the performance of any study specific

- IPF diagnosis within 5 years before study entry, proven according to the American
Thoracic Society/European Respiratory Society consensus conference criteria, with
surgical lung biopsy. In the absence of a surgical lung biopsy, HRCT must be
consistent with usual interstitial pneumonitis.

- Resting state SpO2 ≥ 88% with or without supplemental oxygen, FVC % ≥ 50% normal
predicted value, and DLCO ≥ 30% normal predicted value at baseline

- Men with partners of childbearing potential must be willing to use 2 medically
acceptable methods of contraception during the trial and for 1 month after the last
dose of study drug. Effective birth control includes (a) intrauterine device (IUD)
plus 1 barrier method; (b) stable doses of hormonal contraception for at least 3
months (eg, oral, injectable, implant, transdermal) plus 1 barrier method; (c) 2
barrier methods. Effective barrier methods are male or female condoms, diaphragms,
and spermicides (creams or gels that contain a chemical to kill sperm); or (d)

- Have adequate bone marrow function:

1. ANC > 1500/mm3

2. Hemoglobin > 9.0 g/L

3. Platelets > 100,000/mm3

- Willing to complete all study measurements and assessments in compliance with the

- Has either received pirfenidone and/or nintedanib or has been offered both treatments
(with last dose administered at least 1 month before the expected start of study drug
dosing). If either or both pirfenidone and nintedanib treatment has not been given,
then documentation that the patient was offered both treatments must be documented.

Exclusion Criteria:

- Interstitial lung disease caused by conditions other than IPF

- Severe concomitant illness limiting life expectancy (< 1 year)

- Diffusing capacity of the lung for carbon monoxide (DLCO) < 30% predicted

- Residual volume ≥ 120% predicted

- Obstructive lung disease: FEV1/ FVC ratio < 0.70

- Documented sustained improvement of the subject's IPF condition up to 12 months
before study entry with or without IPF-specific therapy

- Pulmonary or upper respiratory tract infection within 4 weeks before study entry

- Acute or chronic impairment (other than dyspnea) limiting the ability to comply with
study requirements (eg, pulmonary function tests)

- Chronic heart failure with New York Heart Association class III/IV or known left
ventricular ejection fraction < 25%

- Moderate to severe hepatic impairment (ie, Child-Pugh Class B or C)

- Estimated creatinine clearance < 30 mL/min

- Aspartate aminotransferase (AST) and/or ALT > 2.0 × upper limit of normal (ULN)

- Hemoglobin < 75% of the lower limit of normal

- Systolic blood pressure < 100 mmHg

- Men whose partner is pregnant or breastfeeding

- Current drug or alcohol dependence

- Chronic treatment with the following drugs (within 4 weeks of study entry and during
the study)

1. Immunosuppressive or cytotoxic drugs including cyclophosphamide and azathioprine

2. Antifibrotic drugs including pirfenidone, nintedanib, D penicillamine,
colchicine, tumor necrosis factor α blockers, imatinib and interferon-γ

3. Chronic use of N-acetylcysteine prescribed for IPF (> 600 mg/day)

4. Oral anticoagulants prescribed for IPF

- Treatment with endothelin receptor antagonists within 4 weeks before study entry

- Systemic treatment within 4 weeks before study entry with cyclosporine A or
tacrolimus, everolimus, or sirolimus (calcineurin or mammalian target of rapamycin

- Previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK2

- Planned treatment, or treatment with another investigational drug within 4 weeks
before study entry

- Subject is taking a medication that has the potential for QTc prolongation (see
Appendix A)

- Subject is taking a drug that is a sensitive substrate of CYP enzymes

- Subject is taking an inhibitor or inducer of CYP3A4 (see Appendix B)

- Subject has consumed an herbal medication (eg, St. John's Wort) or
grapefruit/grapefruit juice within 14 days prior to the Week 1, Day 1 visit
We found this trial at
Salt Lake City, Utah 84132
Principal Investigator: Mary Beth Scholand, MD
Phone: 801-587-7855
Salt Lake City, UT
Click here to add this to my saved trials
326 North Mills Avenue
Orlando, Florida 32803
Principal Investigator: Syed Mobin, MD
Phone: 407-841-1100
Orlando, FL
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Principal Investigator: Timothy Whelan, MD
Phone: 843-792-8092
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Charleston, SC
Click here to add this to my saved trials
Kissimmee, Florida 34741
Principal Investigator: Thomas O'Brien, MD
Kissimmee, FL
Click here to add this to my saved trials
Phoeniz, Arizona 85006
Principal Investigator: David Baratz, MD
Phone: 602-346-4747
Phoeniz, AZ
Click here to add this to my saved trials
Tucson, Arizona 85721
(520) 621-2211
Principal Investigator: Sachin Chaudhary, MD
Phone: 520-626-8000
University of Arizona The University of Arizona is a premier, public research university. Established in...
Tucson, AZ
Click here to add this to my saved trials